Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding
暂无分享,去创建一个
Joel S. Parker | J. Parker | Y. Whang | M. Karaca | H. Earp | Zhentao Zhang | Mehmet Karaca | Yuanbo Liu | Zhentao Zhang | Dinuka De Silva | H. Shelton Earp | Young E. Whang | Yuanbo Liu | Dinuka M. De Silva | D. Silva | Yuanbo Liu | J. Parker
[1] J. Mohler,et al. Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer , 2012, PLoS ONE.
[2] D. Tindall,et al. Alternatively spliced androgen receptor variants. , 2011, Endocrine-related cancer.
[3] A. Zoubeidi,et al. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer , 2013, Molecular and Cellular Endocrinology.
[4] F. S. French,et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.
[5] K. Waltering,et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. , 2009, Cancer research.
[6] Desok Kim,et al. The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.
[7] J Isola,et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.
[8] James L Mohler,et al. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. , 2005, Cancer research.
[9] Biaoyang Lin,et al. The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[10] J.,et al. The New England Journal of Medicine , 2012 .
[11] J. Mohler,et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation , 2007, Proceedings of the National Academy of Sciences.
[12] S. Balk,et al. Androgen Receptor Phosphorylation and Activity Are Regulated by an Association with Protein Phosphatase 1* , 2009, The Journal of Biological Chemistry.
[13] Zhiyong Guo,et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.
[14] F. Hsu,et al. Regulation of Androgen Receptor and Prostate Cancer Growth by Cyclin-dependent Kinase 5* , 2011, The Journal of Biological Chemistry.
[15] Chris Maloney,et al. PubMed Central , 2017 .
[16] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Coppola,et al. Ack1-mediated Androgen Receptor Phosphorylation Modulates Radiation Resistance in Castration-resistant Prostate Cancer* , 2012, The Journal of Biological Chemistry.
[18] S. Balk,et al. Androgen Receptor Serine 81 Phosphorylation Mediates Chromatin Binding and Transcriptional Activation* , 2012, The Journal of Biological Chemistry.
[19] P. Nelson,et al. Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.
[20] P. Nelson,et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.
[21] E. Wilson,et al. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. , 1993, The Journal of biological chemistry.
[22] K. Mahajan,et al. ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation. , 2013, Cancer letters.
[23] G. Sonpavde. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[24] G. Bubley,et al. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1 , 2006, Proceedings of the National Academy of Sciences.
[25] I. McEwan,et al. Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. , 2008, Biochemistry.
[26] S. Powers,et al. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[27] D. Tindall,et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.
[28] Zhiyong Guo,et al. Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.
[29] Zhiyong Guo,et al. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. , 2010, Cancer research.
[30] W. Hahn,et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. , 2010, Molecular endocrinology.
[31] T. H. van der Kwast,et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. , 1991, Molecular endocrinology.
[32] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[33] K. Tomer,et al. Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.
[34] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[35] Zhiyong Guo,et al. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy , 2014, Oncotarget.
[36] G. Murphy,et al. LNCaP model of human prostatic carcinoma. , 1983, Cancer research.
[37] F. Claessens,et al. Detailed functional studies on androgen receptor mild mutations demonstrate their association with male infertility , 2008, Clinical endocrinology.
[38] B. E. Black,et al. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. , 2006, Molecular endocrinology.
[39] T. Golub,et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.
[40] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[41] D. Coppola,et al. Effect of Ack1 tyrosine kinase inhibitor on ligand‐independent androgen receptor activity , 2010, The Prostate.
[42] Daniel Gioeli,et al. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases , 2010, Oncogene.
[43] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[44] G. Bubley,et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.
[45] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[46] K. Silverstein,et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.
[47] Daniel Gioeli,et al. Post-translational modification of the androgen receptor , 2012, Molecular and Cellular Endocrinology.
[48] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[49] Mahadev Rao,et al. The Androgen Receptor Acetylation Site Regulates cAMP and AKT but Not ERK-induced Activity* , 2004, Journal of Biological Chemistry.